Revised policy for therapies for COVID-19

Having trouble viewing this email? View it as a Web page.

Health Care Authority (HCA) logo

Apple Health (Medicaid) Provider Alert

Attention providers

What changed?

The Health Care Authority (HCA) has updated its COVID-19 therapies policy with information regarding new COVID-19 monoclonal antibodies and Remdesivir.

New COVID-19 monoclonal antibodies

Retroactive for dates of service on and after December 8, 2021, providers may bill HCA for the following monoclonal antibody treatments:

HCPC code Short Description
Q0220 Tixagev and cilgav, 300 mg
M0220 Tixagev and cilgav inj
M0221 Tixagey and cilgay inj hm

Remdesivir (HCPCS code J0248)

Retroactive for dates of service on and after December 23, 2021, HCA may consider Remdesivir to be medically necessary when prescribed for:

  • Adults and pediatric patients 12 years of age or older for the treatment of coronavirus disease (COVID-19)

  • The treatment of pediatric patients weighing at least 3.5 kg but less than 39.99 kg or pediatric patients 11 years of age or younger weighing at least 3.5 kg with suspected or laboratory confirmed COVID-19 for whom use of an intravenous (IV) agent is clinically appropriate

See Therapies for COVID-19 for more information regarding the policy and procedure codes involved.

COVID-19 Fee Schedule

HCA revised the Emergency COVID-19 Fee Schedule. See HCA’s Provider billing guides and fee schedules, under COVID-19.